Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
China Journal of Chinese Materia Medica ; (24): 206-213, 2021.
Article in Chinese | WPRIM | ID: wpr-878931

ABSTRACT

This paper was to investigate the effect of Huanglian Jiedu Decoction(HLJD) on ulcerative colitis(UC) in mice, and determine the effective components in plasma, and virtually screen its therapeutic target, and predict its mechanism. Sixty Balb/c mice were randomly divided into blank group, model group, mesalazine treatment group(0.3 g·kg~(-1)), and HLJD treatment groups(24.66, 12.33, 6.17 g·kg~(-1)). Excepted for the blank group, all the mice in HLJD and mesalazine treatment groups were gavage administration. All mice freely drank 2.5% DSS solution for seven days to induce UC. The disease activity index(DAI) was detected each day. At the end of the experiment, HE staining was used to observe the pathological changes in colon. The content of IL-1β, IL-6 and TNF-α in colon were determined by ELISA. The effective components in plasma were determined by UPLC-Q-TOF-MS. The reverse docking in PharmMapper was used to screen the component targets. The disease targets of UC were collected by searching TTD, OMIM and GeneCards databases. The intersection of the component targets and disease targets was selected as the therapeutic targets. Then the therapeutic targets were imported into the STRING for GO and KEGG enrichment analysis. Discovery Studio was used to simulate the docking between the components and the targets. RESULTS:: showed that the DAI in the model group increased significantly(P<0.05), and the number of inflammatory cells and infiltration degree increased significantly compared with the blank group. The DAI in HLJD treatment group was significantly reduced(P<0.05), and the number and infiltration degree of inflammatory cells were reduced compared with the model group. The ELISA results showed that the levels of IL-1β, IL-6 and TNF-α were increased significantly in the model group(P<0.01) compared with the blank group, and significantly down regulated in the HLJD treatment group(P<0.05) compared with the model group. After UPLC-Q-TOF-MS analyse, ten components were identified. The network pharmacology analysis showed that the action targets were significantly enriched in 129 of biological processes, such as response to organic substance, chemical and oxygen-containing compound, etc., as well as 16 of signal pathways, such as IL-17, TNF and hepatitis B signal pathways, were enriched too. The results of molecular docking showed that limonin, palmatine and berberine could bind to CASP3 and MMP9 by hydrogen bond. In conclusion, HLJD could alleviate the colonic mucosal inflammatory infiltration and mucosal damage in UC mice. The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1β, IL-6 and TNF-α in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.


Subject(s)
Animals , Mice , Anti-Inflammatory Agents/therapeutic use , Colitis, Ulcerative/drug therapy , Colon , Dextran Sulfate/therapeutic use , Drugs, Chinese Herbal , Molecular Docking Simulation , Plasma
2.
Journal of Medical Postgraduates ; (12): 77-82, 2018.
Article in Chinese | WPRIM | ID: wpr-700778

ABSTRACT

Persistent bacteria is a microbial subpopulation which can survive from lethal concentration of antimicrobial agents. Unlike the resistant bacteria which usually acquire the resistance from heritable gene mutations, persisters are genetically identical to regular cells in genome but show a distinct antibiotic tolerant phenotype through a state of dormancy. Once the antimicrobial therapy is removed,the persisters can regrow to a new population and cause the recurrent infectious diseases. The increased threats due to the in-fections and drug tolerance caused by persistent bacteria promote the interests of preventing bacterial persistence. This review discusses the harmfulness of persistent infections, the mechanisms of bacterial persistence and summarizes the different control and eradication strategies,aiming to provide ideas and references for further research.

3.
Journal of Southern Medical University ; (12): 724-726, 2010.
Article in Chinese | WPRIM | ID: wpr-355034

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the clinical efficacy of infliximab in the treatment of moderate and severe active rheumatoid arthritis (RA).</p><p><b>METHODS</b>This randomized double-blind II/III clinical trial involved 30 patients with moderate and severe active RA, who were randomly allocated into 3 groups (groups A, B, and C) at the ratio of 3:1:1. At weeks 0, 2, 6, and 14, the patients in groups A and C received infliximab or placebo, and those in group B had placebo at week 14 with a stable background dose of methotrexate. The indicators for efficacy evaluation included the proportions of ACR20/50/70 of the responders and DAS28. The sharp scores of the hand joints were recorded before and after the treatment.</p><p><b>RESULTS</b>Twenty-nine patients completed the clinical trial (18 in group A, 5 in group B, and 6 in group C). At week 14, the proportions of ACR20/50/70 in the 3 groups reached 83.33%, 60%, and 33.33%, respectively (P<0.05), as compared to 100%, 100%, and 33.33% at week 18 (P<0.05). The other indicators for clinical efficacy evaluation also suggested similar clinical improvement of the patients (P=0.000). The proportions of the patients with DAS28<3.2 and DAS28<2.6 were significantly different. Compared to the baseline, the Sharp scores in group A showed no significant changes at week 18 (P>0.930), while those in group C exhibited significant radiographic progression (P<0.044).</p><p><b>CONCLUSION</b>Infliximab produces good short-term therapeutic effect against moderate and severe active RA and may help arrest the radiographic progression of the diseases, which can be more obvious in patients with moderate severity.</p>


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Antibodies, Monoclonal , Therapeutic Uses , Arthritis, Rheumatoid , Diagnostic Imaging , Therapeutics , Double-Blind Method , Infliximab , Radiography , Tumor Necrosis Factor-alpha , Allergy and Immunology
4.
Journal of Southern Medical University ; (12): 1349-1353, 2010.
Article in Chinese | WPRIM | ID: wpr-336182

ABSTRACT

<p><b>OBJECTIVE</b>To explore the association of the expressions of human leukocyte antigen (HLA)-DR4, peptidyl arginine deiminase type4(PAD4), and signal transducer and activator of transcription 4 (STAT4) in the peripheral blood with the disease activity in patients with rheumatoid arthritis (RA).</p><p><b>METHODS</b>Twenty-four RA patients in active stage (DAS28 score>or=2.6) and 14 RA patients in remission stage (DAS28 score<2.6) were enrolled in this study, with 12 healthy volunteers as the control. The QuantiGene Plex method was used to measure the expression level of HLA-DR4, PAD4, and STAT4 mRNA, and the relationship between the expressions of these genes and the DAS28 score, levels of anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and rheumatoid factor (RF) was analyzed.</p><p><b>RESULTS</b>The expressions of HLA-DR4, PAD4, and STAT4 were significantly higher in RA patients than in the healthy controls (P<0.05). The level of HLA-DR4 mRNA in the two RA groups showed no significant difference, but was significantly higher than that in the healthy controls. HLA-DR4 expression was not found to correlated to DAS28 score, anti-CCP antibody level or RF in the RA patients. The expressions of PAD4 and STAT4 were significantly different between the two RA groups (P<0.05). In the RA patients, PAD4 mRNA expression was positively correlated to DAS28 and anti-CCP antibody level (P<0.05), and STAT4 expression showed positive correlations to DAS28 and RF levels (P<0.05).</p><p><b>CONCLUSION</b>HLA-DR4, PAD4 and STAT4 are overexpressed in RA patients and may be involved in the pathogenesis of RA. The expressions of PAD4 and STAT4, but not HLA-DR4, are closely related to the disease activity of RA. Detection of peripheral blood PAD4 and STAT4 expressions can be helpful for evaluating the disease activity of RA.</p>


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Arthritis, Rheumatoid , Blood , HLA-DR4 Antigen , Blood , Genetics , Metabolism , Hydrolases , Blood , Genetics , Metabolism , Protein-Arginine Deiminases , RNA, Messenger , Genetics , Metabolism , STAT4 Transcription Factor , Blood , Genetics , Metabolism
5.
Journal of Southern Medical University ; (12): 1621-1625, 2008.
Article in Chinese | WPRIM | ID: wpr-340764

ABSTRACT

<p><b>OBJECTIVE</b>To study the antitumor and distant bystander effects of cationic liposome-mediated cytosine deaminase (CD)/5-fluorocytosine (5-FC) suicide gene system combined with interferon-gamma (IFN-gamma) in vivo.</p><p><b>METHODS</b>Murine hepatoma 22 (H22) cells transfected by CD gene were inoculated subcutaneous in Kunming mice in the left axillary region, and the H22 cells without CD gene transfection were inoculated in the right axillary region. The mice were randomly divided into 4 groups and treated with normal saline , 5-FC, IFN-gamma, and 5-FC+ IFN-gamma on a daily basis. The tumor inhibition and distant bystander effects were observed in the mice.</p><p><b>RESULTS</b>Exposure of CD gene-transfected tumor to 5-Fc resulted in obvious tumor growth inhibition with an inhibition rate of 78.38%, which was significantly increased to 93.21% (P<0.01) with 5-Fc +IFN-gamma treatment. A notable distant bystander effect in the CD/5-FC suicide gene system was observed in vivo, with a tumor inhibition rate of was 54.42%; when combined with IFN-gamma, the inhibition rate increased significantly to 87.57% (P<0.05).</p><p><b>CONCLUSION</b>When combined with IFN-gamma, CD/5-FC suicide system has stronger anti-tumor and distant bystander effects. CD/5-FC suicide gene system combined with IFN-gamma may provide a potential therapy for malignant tumors.</p>


Subject(s)
Animals , Male , Mice , Bystander Effect , Cations , Chemistry , Cytosine Deaminase , Genetics , Flucytosine , Pharmacology , Genes, Transgenic, Suicide , Genetics , Genetic Therapy , Methods , Interferon-gamma , Therapeutic Uses , Liposomes , Liver Neoplasms, Experimental , Therapeutics , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL